1-(1,4-dioxan-2-yl)ethanamine | 1450660-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 1-(1,4-dioxan-2-yl)ethanamine
• 英文别名: 1-(1,4-Dioxan-2-yl)ethan-1-amine
• CAS: 1450660-61-3
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: YBMCUQGJDWTFOO-UHFFFAOYSA-N

物化性质

• 沸点：
  200.1±15.0 °C(Predicted)
• 密度：
  1.026±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-溴苯基)-3-氧代丁酸甲酯 、 1-(1,4-dioxan-2-yl)ethanamine 在 溶剂黄146 作用下， 以 甲醇 为溶剂， 以14%的产率得到(E)-methyl 3-((1-(1,4-dioxan-2-yl)ethyl)imino)-2-(2-bromophenyl)butanoate
  参考文献：
  名称：

  [EN] MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
  [FR] MODULATEURS D'ENZYMES DE MODIFICATION PAR MÉTHYLATION, COMPOSITIONS ET UTILISATIONS ASSOCIÉES

  摘要：

  本文提供了具有结构式（II）的调节组蛋白甲基修饰酶的药剂、组合物及用途，例如作为抗癌剂。

  公开号：

  WO2014124418A1
• 作为产物：
  描述：

  N-methoxy-N-methyl-1,4-dioxane-2-carboxamide 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， -78.0~20.0 ℃ 、206.85 kPa 条件下， 反应 13.0h， 生成 1-(1,4-dioxan-2-yl)ethanamine
  参考文献：
  名称：

  [EN] TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
  [FR] COMPOSÉS DE TRIAZOLE PYRIDYLE EN TANT QU'AGONISTES DU RÉCEPTEUR APJ

  摘要：

  化合物I和化合物II，其药用可接受盐，上述任何的立体异构体，或它们的混合物是APJ受体的激动剂，可能用于治疗心血管和其他疾病。化合物I和化合物II的结构如下，其中变量的定义在此处提供。

  公开号：

  WO2018093580A1

文献信息

• CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES
  申请人：Cypralis Limited

  公开号：US20150259386A1

  公开（公告）日：2015-09-17

  The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.

  本发明涉及一种新型环十一肽类化合物及其类似物，其能够结合并抑制环孢菌素，具有降低的免疫抑制活性和改善的物理化学性质，包括水溶性。本发明还涉及包含所述depsipeptide化合物及其类似物的药物组合物，用于治疗或预防可能通过抑制环孢菌素活性而改善的疾病和病理状态。
• MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
  申请人：CONSTELLATION PHARMACEUTICALS, INC.

  公开号：US20150376190A1

  公开（公告）日：2015-12-31

  Agents having the structural Formula (II) for modulating histone methyl modifying enzymes, compositions and uses thereof for instance as anti-cancer agents are provided herein.

  本文提供了具有结构式（II）的制剂，用于调节组蛋白甲基修饰酶，例如作为抗癌制剂的组合物和用途。
• PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Bernardelli Patrick

  公开号：US20090281084A1

  公开（公告）日：2009-11-12

  The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及具有苯基的苯基-1,2,4-噁二唑酮衍生物及其生理上可接受的盐和生理上功能衍生物，显示PPARδ激动剂活性。所描述的是式I的化合物，其中基团如定义所述，以及它们的生理上可接受的盐和它们的制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的障碍以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：Bernardelli Patrick

  公开号：US20080287409A1

  公开（公告）日：2008-11-20

  The present invention comprises phenyl and pyridinyl 1,2,4-oxadiazolone compounds their physiologically acceptable salts and physiologically functional derivatives that exhibit peroxisome proliferator activator receptor (PPAR) delta agonist activity. Also described and claimed are processes for their preparation and their use as pharmaceuticals. These are compounds of formula I, in which the R-group substituents are defined herein. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and de-myelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及苯基和吡啶基1,2,4-噁二唑酮化合物及其生理上可接受的盐和生理功能衍生物，其表现出过氧化物酶体增殖物激活受体（PPAR）δ激动剂活性。还描述和声明了它们的制备过程以及它们作为药物的用途。这些化合物的化学式为I，其中R基取代基在此定义。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病，以及中枢和外周神经系统的去髓鞘和其他神经退行性疾病。
• Modulators of methyl modifying enzymes, compositions and uses thereof
  申请人：Constellation—Pharmaceuticals, Inc.

  公开号：US09085583B2

  公开（公告）日：2015-07-21

  Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

  本文提供了调节甲基修饰酶的代理、组合物及其用途。